The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives

Trastuzumab was the first targeted therapy for HER2 positive breast cancer. It has become the standard of care for HER2 positive metastatic breast cancer since 2000 and in the adjuvant setting since 2006. Adjuvant it is given for a year and in patients with metastatic disease until progression. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadmitriou, K., Trinh, X.B., Altintas, S., Van Dam, P.A., Huizing, M.T., Tjalma, W.A.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universa Press 2015
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788333/
https://www.ncbi.nlm.nih.gov/pubmed/26977267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788333/
https://www.ncbi.nlm.nih.gov/pubmed/26977267

Ejemplares similares